Comparative Pharmacology
Head-to-head clinical analysis: BENLYSTA versus KESIMPTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENLYSTA versus KESIMPTA.
BENLYSTA vs KESIMPTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Belimumab is a human IgG1λ monoclonal antibody that binds to soluble B-lymphocyte stimulator (BLyS, also known as BAFF), inhibiting its activity. BLyS is a cytokine that promotes B-cell survival and differentiation. By binding BLyS, belimumab reduces the survival of B cells, including autoreactive B cells, and decreases the production of autoantibodies.
KESIMPTA (ofatumumab) is a fully human anti-CD20 monoclonal antibody that selectively binds to the CD20 antigen on B lymphocytes, leading to B-cell lysis via complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC). This results in depletion of circulating B cells, reducing inflammatory demyelination in multiple sclerosis.
10 mg/kg IV over 1 hour at 2-week intervals for the first 3 doses, then 10 mg/kg IV every 4 weeks; or 200 mg SC once weekly (after loading dose of 200 mg SC weekly for 4 doses for SC initiation).
20 mg administered subcutaneously once monthly after a loading dose of 20 mg on Days 0, 7, and 14.
None Documented
None Documented
Terminal half-life approximately 18.6 days (range 13–31 days) in patients with SLE, supporting monthly intravenous dosing.
16 days (range 13–20 days) with linear pharmacokinetics; supports every 4-week dosing.
Not extensively characterized; expected to be degraded into small peptides and amino acids via general protein catabolism. Renal and fecal elimination are minor pathways.
Primarily degraded into small peptides and amino acids; not excreted renally or fecally as intact drug. Elimination pathways not fully characterized due to monoclonal antibody catabolism.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody, Anti-CD20